ZNF384 is a C2H2-type zinc finger transcription factor that binds the consensus DNA sequence [GC]AAAAA and regulates promoters of genes including MMP1, MMP3, MMP7, and COL1A1. In normal physiology, ZNF384 functions as a sequence-specific DNA-binding protein localized to the nucleus, binding zinc ions for structural stability 1. ZNF384 is clinically significant primarily as a recurrent fusion partner in acute lymphoblastic leukemia (ALL). Over 19 different ZNF384 fusion partners have been identified in ALL, including EP300, CREBBP, TCF3, TAF15, EWSR1, and others 1. The EP300-ZNF384 fusion was demonstrated to induce leukemia in mice and perturbs B-cell differentiation 2. ZNF384 rearrangements occur in both B-ALL and mixed phenotype acute leukemia (B/M MPAL), where they are particularly common 3. Clinically, ZNF384-rearranged ALL patients have intermediate-risk disease with 5-year overall survival of 33-45% in adult cohorts 4. Single-cell analysis reveals that ZNF384-rearranged B-ALL shows enrichment of hematopoietic stem cells in its cellular composition 5. Interestingly, ZNF384 has been identified as a predicted transcription factor regulating genes (PPARG, ZNF415, HLX, ANHX) implicated in inflammation and metabolism dysregulation in psoriasis and Alzheimer's disease 6, suggesting potential broader biological roles beyond leukemia.